112 results
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
2 May 24
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
7:09am
upcoming investor conferences:
Citizens JMP Life Sciences Conference on Monday, May 13, 2024 at 10:00 am ET.
Goldman Sachs 45th Annual Global Healthcare
8-K
BPMC
Blueprint Medicines Corp
22 Feb 24
Other Events
8:20am
(the “Roche Collaboration”), enables the transition of GAVRETO to Rigel in the United States and, as previously announced at the J.P. Morgan Healthcare
8-K
EX-99.1
ctfcdrr
15 Feb 24
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
7:05am
8-K
EX-99.1
v8e90har 4e
8 Jan 24
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
8:03am
8-K
EX-99.2
3vz9rflazx8gqu6k
8 Jan 24
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
8:03am
8-K
y1nd1
8 Jan 24
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
8:03am
8-K
EX-99.1
2xjj1 ivf
26 Oct 23
Blueprint Medicines Reports Third Quarter 2023 Results
7:00am
8-K
EX-99.2
nb610yib
2 Aug 23
Blueprint Medicines Reports Second Quarter 2023 Results
7:00am
8-K
EX-99.1
kfouh2ayi711wm8av4ui
2 Aug 23
Blueprint Medicines Reports Second Quarter 2023 Results
7:00am
8-K
ak8g7i1tf53
30 Jun 23
Other Events
6:03am
8-K
EX-99.1
4jpmd3x01o605c4
22 May 23
FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis
4:53pm
8-K
EX-99.1
f7un2bxqdzcibplfva
4 May 23
Blueprint Medicines Reports First Quarter 2023 Results
7:18am